2026. Nanotechnology-Driven Bioavailability Enhancement: A Critical Review of BCS Class II and IV Drugs. Journal of Drug Discovery and Health Sciences. 3, 03 (Sep. 2026), 63–71. DOI:https://doi.org/10.21590/d40skq78.